Cipla Limited
CIPLA
Helyezés a részvények között
#1814
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Részvényárfolyam
$14.61
Utolsó szinkronizálás: 2026-10-19
Piaci kapitalizáció
$11.81B
Változás (1 nap)
-0.11%
Változás (1 év)
-21.65%
Ország
IN
Kereskedés Cipla Limited (CIPLA)
Kategória
Healthcare
Cipla Limited (CIPLA) nyeresége
Nyereség ekkor: Jun 2026 TTM: $499.57M
Cipla Limited legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi nyeresége $499.57M. 2024 évben a vállalat $683.63M nyereséget ért el, növekedés a 2023 év nyereségéhez, amely $491.08M volt. Az ezen az oldalon megjelenített nyereség a kamatok és adók előtti eredmény, azaz EBIT.
Cipla Limited nyereségtörténete 2004 és 2026 között
Nyereség az év végén
| Év | Nyereség | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $499.57M | -37.16% |
| 2025 | $794.95M | 16.28% |
| 2024 | $683.63M | 39.21% |
| 2023 | $491.08M | 7.11% |
| 2022 | $458.50M | 2.41% |
| 2021 | $447.69M | 58.29% |
| 2020 | $282.83M | -4.75% |
| 2019 | $296.94M | 16.00% |
| 2018 | $255.98M | 36.61% |
| 2017 | $187.39M | -27.61% |
| 2016 | $258.87M | -0.84% |
| 2015 | $261.05M | -3.94% |
| 2014 | $271.76M | -29.32% |
| 2013 | $384.50M | 34.66% |
| 2012 | $285.52M | 9.46% |
| 2011 | $260.85M | -11.65% |
| 2010 | $295.26M | 67.39% |
| 2009 | $176.40M | -15.76% |
| 2008 | $209.41M | 12.35% |
| 2007 | $186.39M | 16.95% |
| 2006 | $159.38M | 35.23% |
| 2005 | $117.85M | 26.61% |
| 2004 | $93.09M | 0.00% |
Hasonló cégek vagy versenytársak nyeresége
| Vállalat | Nyereség | Nyereségkülönbség | Ország |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 253.21% |
IN
|
